Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof

a technology of histone deacetylase and cytodifferentiating agent, which is applied in the field of new cytodifferentiating agent and histone deacetylase inhibitors, can solve the problems of limited potency of hmba, and achieve the effect of inhibiting proliferation

Inactive Publication Date: 2007-01-11
SLOAN KETTERING INST FOR CANCER RES +1
View PDF34 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these phase I clinical trials also have demonstrated that the potential efficacy of HMBA is limited, in part, by dose-related toxicity which prevents achieving optimal blood levels and by the need for intravenous administration of large quantities of the agent, over prolonged periods.
However, U.S. Pat. No. 5,369,108 does not disclose that an additional large hydrophobic group at the same end of the molecule as the first hydrophobic group would further increase differentiation activity about 100 fold in an enzymatic assay and about 50 fold in a cell differentiation assay.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
  • Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
  • Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Synthesis of Compound 1

[0086] N-Boc-ω-methyl-(L)-α-aminosuberate, Boc-Asu (OMe) was prepared according to a published procedure (40). (“Boc”=t-butoxycarbonyl; “Asu”=α-aminosuberate (or α-aminosuberic acid))

[0087] N-Cbz-ω-t-butyl-(L)-α-aminosuberate, dicyclohexylamine salt was purchased from Research Plus, Bayonne, N.J.

N-Boc-ω-methyl-(L)-α-aminosuberateanilide, Boc-Asu(OMe)-NHPh

[0088]

[0089] N-Boc-ω-methyl-(L)-α-aminosuberate (493 mg, 1.63 mmoles) was dissolved under Ar in 7 mL of dry CH2Cl2. EDC (470 mg, 2.45 mmoles) was added, followed by aniline (230 μL, 2.52 mmoles). The solution was stirred at room temperature for 2 h 30 min, then washed with dilute HCl (pH 2.4, 2×5 mL), sat. NaHCO3 (10 mL), and H2O (2×10 mL). The product was purified by column chromatography (Silica gel, Hexanes:AcOEt 3.5:1). The isolated yield was 366 mg (60%).

[0090]1H-NMR and Mass Spectroscopy were consistent with the product.

N-Benzoyl-ω-methyl-(L)-α-aminosuberateanilide, PhCOHN-Asu(OMe)-NHPh

[0091]

[0092...

example 2

Synthesis of Compound 2

N-Nicotinoyl-(L)-α-aminosuberoylanilide-ω-hydroxamic acid, C5H4NCO-Asu (NHOH)—NHPh

[0102]

[0103] It was prepared from N-Boc-ω-methyl-L-α-aminosuberate following the same procedure used for the benzoyl analog. Yields and chromatographic behaviour were comparable.

[0104]1H-NMR (d6-DMSO, 500MHz) δ=10.30 (s, 1H), 10.10 (s, 1H), 9.05 (m, 1H), 8.80 (m, 1H), 8.71 (m, 1H), 8.24 (m, 1H), 7.60 (m, 2H), 7.30 (m, 2H), 7.04 (m, 1H), 4.56 (m, 1H), 1.93 (t, 2H), 1.79 (m, 2H), 1.55-1.30 (m, 6H). ESI-MS: 385 (M+1), 407 (M+Na)

example 3

Synthesis of Compound 3

N-benzyloxycarbonyl-ω-t-butyl-(L)-aminosuberic acid, N-Cbz-(L)-Asu (OtBu)-OH

[0105]

[0106] N-Cbz-(L)-Asu (OtBu)-OH, dicyclohexylamine salt (100 mg, 0.178 mmol) was partitioned between 1 M HCl (5 mL) and EtOAc (10 mL). The organic layer was removed, and the aqueous portion washed with EtOAc (3×3 mL). The organic fractions were combined, washed with brine (1×2 mL), and dried (MgSO4). The mixture was filtered and concentrated to a colorless film (67 mg, 0.176 mmol, 99%). This compound was used immediately in the next step.

N-benzyloxycarbonyl-ω-t-butyl-(L)-α-aminosuberateanilide, N-Cbz-(L)-Asu (OtBu)-NHPh

[0107]

[0108] N-Cbz-(L)-Asu (OtBu)-OH (67 mg, 0.176 mmol) was dissolved in dry CH2Cl2 (2.5 mL). Aniline (17 μL, 0.187 mmol), PyBOP (97 mg, 0.187 mmol), and iPr2NEt (46 μL, 0.266 mmol) were added and the mixture stirred for 2 h. The reaction was complete as indicated by TLC. The mixture was diluted with EtOAc (5 mL) and water (5 mL), and the layers separated. The ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides the compound having the formula: wherein each of R1 and R2 is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or pyridine group; wherein A is an amido moiety, —O—, —S—, —NH—, or —CH2—; and wherein n is an integer from 3 to 8. The present invention also provides a method of selectively inducing growth arrest, terminal differentiation and / or apoptosis of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of the compound above.

Description

RELATED APPLICATIONS [0001] This application is a continuation of U.S. application Ser. No. 09 / 645,430, filed Aug. 24, 2000 which claims the benefit of U.S. Provisional Application 60 / 208,688 filed Jun. 1, 2000 and U.S. Provisional Application 60 / 152,755; filed Sep. 8, 1999. [0002] Throughout this application various publications are referenced by Arabic numerals within parentheses. Full citation for these publications may be found at the end of the specification immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.BACKGROUND OF THE INVENTION [0003] Cancer is a disorder in which a population of cells has become, in varying degrees, unresponsive to the control mechanisms which normally govern proliferation and differentiation. A recent approach to cancer therapy has been to attempt induction of terminal...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/52A61K31/445A61K31/44C07C259/04A61K31/165A61K31/27A61K31/4406A61K31/47A61P35/00A61P43/00C07C69/602C07C69/604C07C69/716C07C233/12C07C233/13C07C233/30C07C237/22C07C237/52C07C259/06C07C271/22C07C311/03C07C311/06C07C311/42C07C323/67C07C327/32C07D213/75C07D213/82C07D215/38C07D215/40C07D215/54C07D231/40C07D233/54C07D277/46C07D333/38C07D521/00C07F9/24C07F9/36C07F9/44
CPCC07C233/07C07F9/4465C07C235/74C07C237/12C07C237/22C07C259/06C07C271/22C07C311/03C07C311/06C07C311/42C07C327/32C07C2101/14C07D213/75C07D213/82C07D215/38C07D215/40C07D215/54C07D231/12C07D231/40C07D233/56C07D233/64C07D249/08C07D277/46C07D333/38C07F9/2458C07C233/13C07C2601/14A61P35/00A61P43/00C07C235/72
Inventor BRESLOW, RONALDBELVEDERE, SANDROGERSHELL, LELANDMILLER, THOMAS A.MARKS, PAUL A.RICHON, VICTORIA M.RIFKIND, RICHARD A.
Owner SLOAN KETTERING INST FOR CANCER RES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com